Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
$2.38
$2.07
$10.85
$61.05MN/A171,558 shs43,600 shs
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1.38
-11.5%
$1.65
$0.63
$2.75
$73.78M0.961.09 million shs6.99 million shs
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$8.30
+1.9%
$7.37
$3.34
$16.50
$23.15M1.0933,185 shs8,486 shs
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
$1.48
$1.50
$0.63
$1.91
$172.94M-0.05474,959 shs106,384 shs
Exicure, Inc. stock logo
XCUR
Exicure
$7.03
-3.3%
$8.80
$1.44
$36.00
$44.42M3.57578,282 shs18,898 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
0.00%0.00%0.00%0.00%0.00%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
0.00%-19.34%-5.45%+87.59%0.00%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
0.00%+10.15%+8.24%+90.01%-15.21%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00%-3.90%-4.52%+84.98%+83.17%
Exicure, Inc. stock logo
XCUR
Exicure
0.00%+13.06%-17.01%-38.02%+2,101.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/AN/AN/AN/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.7634 of 5 stars
3.24.00.00.03.02.50.0
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
3.2133 of 5 stars
3.55.00.00.02.21.70.6
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
1.3564 of 5 stars
0.05.00.00.03.11.70.0
Exicure, Inc. stock logo
XCUR
Exicure
1.5191 of 5 stars
0.03.00.04.73.30.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
0.00
N/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.40
Hold$7.00407.25% Upside
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
3.00
Buy$40.00382.10% Upside
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00
N/AN/AN/A
Exicure, Inc. stock logo
XCUR
Exicure
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TLSA, XCUR, SLGL, HTBX, and MIST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/5/2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$5.00
(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/AN/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1M73.77N/AN/A$0.25 per share5.52
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$11.54M2.01N/AN/A$10.36 per share0.80
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/A$0.04 per shareN/A
Exicure, Inc. stock logo
XCUR
Exicure
N/AN/AN/AN/A$1.12 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$41.52M-$0.78N/AN/AN/AN/A-329.85%-67.20%8/6/2025 (Estimated)
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-$10.58M-$4.70N/AN/AN/A-107.78%-43.98%-35.28%8/15/2025 (Estimated)
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-$11.86MN/A0.00N/AN/AN/AN/A8/5/2025 (Estimated)
Exicure, Inc. stock logo
XCUR
Exicure
-$9.70M-$3.82N/AN/AN/A-219.60%-82.03%8/11/2025 (Estimated)

Latest TLSA, XCUR, SLGL, HTBX, and MIST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/27/2025Q1 2025
Exicure, Inc. stock logo
XCUR
Exicure
N/A-$0.45N/A$0.49N/AN/A
5/23/2025Q1 2025
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/A-$3.20N/A-$3.20N/A$1.03 million
5/14/2025Q1 2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$0.19-$0.31-$0.12-$0.31N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
N/AN/AN/AN/AN/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/AN/AN/AN/AN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/AN/A
Exicure, Inc. stock logo
XCUR
Exicure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
4.06
4.67
4.67
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/A
5.12
5.12
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A
1.02
1.02
Exicure, Inc. stock logo
XCUR
Exicure
N/A
2.91
2.91

Institutional Ownership

CompanyInstitutional Ownership
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
86.18%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
26.18%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A
Exicure, Inc. stock logo
XCUR
Exicure
42.82%
CompanyEmployeesShares OutstandingFree FloatOptionable
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
4925.65 millionN/AOptionable
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
3053.46 million43.04 millionOptionable
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
502.79 million933,000Optionable
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
8116.85 million70.32 millionOptionable
Exicure, Inc. stock logo
XCUR
Exicure
506.32 million5.79 millionNot Optionable

Recent News About These Companies

Exicure Shares Up After Swing to Profit in 1Q
Why Exicure Inc. (XCUR) Soared on Monday
Exicure announces issuance of new patent in Australia
Kuehn Law Encourages Investors of Exicure, Inc. to Contact Law Firm
Exicure announces purchase agreement with GPCR Therapeutics

New MarketBeat Followers Over Time

Media Sentiment Over Time

Heat Biologics stock logo

Heat Biologics NASDAQ:HTBX

Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

Milestone Pharmaceuticals stock logo

Milestone Pharmaceuticals NASDAQ:MIST

$1.38 -0.18 (-11.54%)
Closing price 04:00 PM Eastern
Extended Trading
$1.40 +0.02 (+1.45%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Sol-Gel Technologies stock logo

Sol-Gel Technologies NASDAQ:SLGL

$8.30 +0.16 (+1.93%)
Closing price 03:59 PM Eastern
Extended Trading
$8.04 -0.26 (-3.10%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Tiziana Life Sciences stock logo

Tiziana Life Sciences NASDAQ:TLSA

$1.48 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.52 +0.04 (+3.04%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Exicure stock logo

Exicure NASDAQ:XCUR

$7.03 -0.24 (-3.30%)
Closing price 04:00 PM Eastern
Extended Trading
$7.01 -0.02 (-0.28%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.